| Title |
Prognostic value of O6-methylguanine-DNA methyltransferase status in glioblastoma patients, assessed by five different methods
|
|---|---|
| Published in |
Journal of Neuro-Oncology, October 2009
|
| DOI | 10.1007/s11060-009-0031-1 |
| Pubmed ID | |
| Authors |
Lucie Karayan-Tapon, Véronique Quillien, Joëlle Guilhot, Michel Wager, Gaëlle Fromont, Stephan Saikali, Amandine Etcheverry, Abderrahmane Hamlat, Delphine Loussouarn, Loïc Campion, Mario Campone, François-Marie Vallette, Catherine Gratas-Rabbia-Ré |
| Abstract |
This multicenter study assesses the value of O(6)-methylguanine-DNA methyltransferase (MGMT) status for predicting overall survival in glioblastoma patients. Five methods are used, to identify the approach with the best prognostic value. Eighty-one tumors were obtained from patients with glioblastomas treated by surgery and radiotherapy with concomitant temozolomide (TMZ) followed by adjuvant TMZ. MGMT promoter methylation was assessed by qualitative methyl-specific polymerase chain reaction (MSP), semiquantitative methyl-specific polymerase chain reaction (SQ-MSP), and pyrosequencing, while MGMT expression was measured at the RNA level by quantitative real-time PCR (Q-RT-PCR) and at the protein level by immunohistochemistry (IHC). MGMT promoter methylation as evaluated by MSP, SQ-MSP, and pyrosequencing was significantly correlated with overall survival. The best predictive value was obtained by pyrosequencing of one specific CpG position. Overall survival was 14 and 25 months for patients with percentages of methylation below and above the median, respectively. In contrast, MGMT status determined by Q-RT-PCR and IHC showed little or no correlation with overall survival, respectively. These results confirm the prognostic value of MGMT promoter methylation in glioblastoma patients initially treated with TMZ. SQ-MSP allowed better discrimination than classical MSP, and pyrosequencing represented a good option. |
Mendeley readers
The data shown below were compiled from readership statistics for 73 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Germany | 1 | 1% |
| France | 1 | 1% |
| Brazil | 1 | 1% |
| United Kingdom | 1 | 1% |
| China | 1 | 1% |
| Japan | 1 | 1% |
| Unknown | 67 | 92% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 13 | 18% |
| Researcher | 12 | 16% |
| Student > Bachelor | 9 | 12% |
| Student > Doctoral Student | 8 | 11% |
| Other | 8 | 11% |
| Other | 11 | 15% |
| Unknown | 12 | 16% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 34 | 47% |
| Biochemistry, Genetics and Molecular Biology | 12 | 16% |
| Agricultural and Biological Sciences | 8 | 11% |
| Neuroscience | 2 | 3% |
| Chemistry | 2 | 3% |
| Other | 1 | 1% |
| Unknown | 14 | 19% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 24 June 2010.
All research outputs
#17,932,284
of 26,017,215 outputs
Outputs from Journal of Neuro-Oncology
#2,294
of 3,329 outputs
Outputs of similar age
#95,865
of 111,565 outputs
Outputs of similar age from Journal of Neuro-Oncology
#19
of 23 outputs
Altmetric has tracked 26,017,215 research outputs across all sources so far. This one is in the 20th percentile – i.e., 20% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,329 research outputs from this source. They receive a mean Attention Score of 4.5. This one is in the 25th percentile – i.e., 25% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 111,565 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 8th percentile – i.e., 8% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 23 others from the same source and published within six weeks on either side of this one. This one is in the 13th percentile – i.e., 13% of its contemporaries scored the same or lower than it.